Abstract
Neuroendocrine tumors (NETs) are rare neoplasms originating from neuroendocrine cells and characterized by the property of producing hormones and biogenic amines. NETs can present an indolent clinical course, thus diagnosis may be delayed when disease is at an advanced stage. A number of different techniques can be applied for NET diagnosis and localization: magnetic resonance, contrast-enhanced computed tomography, gastrointestinal endoscopy, and ultrasonography. Since NETs are known to overexpress somatostatin receptors, somatostatin receptor scintigraphy (SRS) with 111In-pentetreotide has been widely used for NET diagnosis, staging and monitoring response to treatment. Nevertheless, conventional scintigraphic approach presents some limitations due to poor spatial resolution. Positron emission tomography (PET) with 18F-fluorodeoxyglucose has a limited role for the imaging of NETs that are slow-growing neoplasms with reduced expression of glucose transporter receptors. To overcome these drawbacks, three different radiopharmaceuticals binding to somatostatin receptors have been introduced: 68Ga-DOTA-Phe1-Tyr3-Octreotide (TOC), 68Ga-DOTA-NaI3-Octreotide (NOC), and 68Ga-DOTA-Tyr3-Octreotate (TATE). This chapter is aimed to review these 68Ga-DOTA-compounds with particular emphasis on their synthesis, pharmacokinetic/pharmacodynamic properties and on the clinical application in NETs diagnosis and follow-up.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- CT:
-
Computed tomography
- DOTA:
-
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid
- FDG:
-
18fluorodeoxyglucose
- MRI:
-
Magnetic resonance imaging
- NET:
-
Neuroendocrine tumors
- PET:
-
Positron emission tomography
- PRRT:
-
Peptide receptor radionuclide therapy
- SRS:
-
Somatostatin receptor scintigraphy
- US:
-
Ultrasonography
References
Wadas TJ, Wong EH, Weisman GR, et al. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev. 2010;110(5):2858–902.
Antunes P, Ginj M, Zhang H, et al. The renaissance of the Ge/Ga radionuclide generator initiates new developments in Ga radiopharmaceutical chemistry. Curr Top Med Chem. 2010;10(16):1633–68.
Breeman WA, De Jong M, Visser TJ, et al. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging. 2003;30(6):917–20.
Antunes P, Ginj M, Zhang H, et al. Are radiogallium-labelled DOTA conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging. 2007;34(7):982–93.
Breeman WA, de Blois E, Sze Chan H, et al. (68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives. Semin Nucl Med. 2011;41(4):314–21.
Reubi JC, Waser B, Schaer JC, et al. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 2001;28(7):836–46.
Poeppel TD, Binse I, Petersenn S, et al. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med. 2011;52(12):1864–70.
Hofmann M1, Maecke H, Börner R, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med. 2001;28(12):1751–7.
Prasad V, Baum RP. Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions. Q J Nucl Med Mol Imaging. 2010;54(1):61–7.
Reubi JC, Schaer JC, Markwalder R, et al. Distribution of somatostatin receptors in normal and neoplastic human tissues: recent advances and potential relevance. Yale J Biol Med. 1997;70(5–6):471–9.
Rindi G, Petrone G, Inzani F. The 2010 WHO classification of digestive neuroendocrine neoplasms: a critical appraisal four years after its introduction. Endocr Pathol. 2014;25(2):186–92.
Sommer WH, Zech CJ, Bamberg F, et al. Fluid-fluid level in hepatic metastases: a characteristic sign of metastases of neuroendocrine origin. Eur J Radiol. 2012;81(9):2127–32.
Sankowski AJ, Ćwikla JB, Nowicki M, et al. The clinical value of MRI using single-shot echoplanar DWI to identify liver involvement in patients with advanced gastroenteropancreatic-neuroendocrine tumors (GEP-NETs), compared to FSE T2 and FFE T1 weighted image after i.v. Gd-EOB-DTPA contrast enhancement. Med Sci Monit. 2012;18(5):MT33–40.
Song YS, Lee WW, Chung JH, et al. Correlation between FDG uptake and glucose transporter type 1 expression in neuroendocrine tumors of the lung. Lung Cancer. 2008;61(1):54–60.
Kowalski J, Henze M, Schuhmacher J, et al. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol. 2003;5(1):42–8.
Gabriel M, Decristoforo C, Kendler D, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48(4):508–18.
Putzer D, Gabriel M, Henninger B, et al. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med. 2009;50(8):1214–21.
Haug AR, Cindea-Drimus R, Auernhammer CJ, et al. The role of 68Ga-DOTATATE PET/CT in suspected neuroendocrine tumors. J Nucl Med. 2012;53(11):1686–92.
Treglia G, Castaldi P, Rindi G, et al. Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine. 2012;42(1):80–7.
Kabasakal L, Demirci E, Ocak M, et al. Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012;39(8):1271–7.
Wild D, Bomanji JB, Benkert P, et al. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2013;54(3):364–72.
Boy C, Heusner TA, Poeppel TD, et al. 68Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax. Eur J Nucl Med Mol Imaging. 2011;38(7):1224–36.
Campana D, Ambrosini V, Pezzilli R, et al. Standardized uptake values of (68)Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors. J Nucl Med. 2010;51(3):353–9.
Bodei L, Ferone D, Grana CM, et al. Peptide receptor therapies in neuroendocrine tumors. J Endocrinol Invest. 2009;32(4):360–9.. Review
Bodei L, Pepe G, Paganelli G. Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues. Eur Rev Med Pharmacol Sci. 2010;14(4):347–51.. Review
Falletta S, Partelli S, Rubini C, et al. mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2016. pii: ERC-16-0329
Kratochwil C, Stefanova M, Mavriopoulou E, et al. SUV of [68Ga]DOTATOC-PET/CT predicts response probability of PRRT in neuroendocrine tumors. Mol Imaging Biol. 2015;17(3):313–8.
Haug AR, Auernhammer CJ, Wängler B, et al. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med. 2010;51(9):1349–56.
Filippi L, Scopinaro F, Pelle G, et al. Molecular response assessed by (68)Ga-DOTANOC and survival after (90)Y microsphere therapy in patients with liver metastases from neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2016;43(3):432–40.
Naji M, Zhao C, Welsh SJ, et al. 68Ga-DOTA-TATE PET vs. 123I-MIBG in identifying malignant neural crest tumours. Naji Mol Imaging Biol. 2011;13(4):769–75.
Kroiss A, Shulkin BL, Uprimny C, et al. (68)Ga-DOTATOC PET/CT provides accurate tumour extent in patients with extraadrenal paraganglioma compared to (123)I-MIBG SPECT/CT. Eur J Nucl Med Mol Imaging. 2015;42(1):33–41.
Rinzivillo M, Partelli S, Prosperi D, et al. Clinical usefulness of 18F-fluorodeoxyglucose positron emission tomography in the diagnostic algorithm of advanced Entero-pancreatic neuroendocrine neoplasms. Oncologist. 2018;23(2):186–92.
Filippi L, Schillaci O, Cianni R, et al. Imaging neuroendocrine hepatic metastases following 90Y-Radioembolization: is it time to implement routine use of PET molecular/metabolic probes? Cardiovasc Intervent Radiol. 2019;42(6):933–4. https://doi.org/10.1007/s00270-019-02186-w.
Kayani I, Bomanji JB, Groves A, et al. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (Dota-DPhe1Tyr-octreotate) and 18F-FDG. Cancer. 2008;112(11):2447–55.
Panagiotidis E, Alshammari A, Michopoulou S, et al. Comparison of the impact of 68Ga-DOTATATE and 18F-FDG PET/CT on clinical management in patients with neuroendocrine tumors. J Nucl Med. 2016. pii: jnumed.116.178095
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Filippi, L., Pizzichini, P., Bagni, O., Scopinaro, F. (2020). Somatostatin Receptor Analogs (68Ga-DOTATOC, 68Ga-DOTANOC, 68Ga-DOTATATE). In: Calabria, F., Schillaci, O. (eds) Radiopharmaceuticals. Springer, Cham. https://doi.org/10.1007/978-3-030-27779-6_6
Download citation
DOI: https://doi.org/10.1007/978-3-030-27779-6_6
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-27778-9
Online ISBN: 978-3-030-27779-6
eBook Packages: MedicineMedicine (R0)